ABBV AbbVie Inc

By Matt Grossman

AbbVie Inc. on Wednesday posted increases in earnings and revenue for the fourth quarter, as sales rose across the segments that make up the company's portfolio of medical treatments.

The Chicago-based pharmaceutical company logged earnings of $2.25 a share, up from one cent a share a year earlier. Total net earnings were $4.04 billion, up from $36 million.

Stripping out one-time items, AbbVie's adjusted earnings were $3.31 a share. Analysts polled by FactSet had forecast adjusted earnings of $3.28 a share.

Revenue rose to $14.89 billion from $13.86 billion, it said. Analysts had been expecting revenue of $14.95 billion.

Immunology sales were up 13% to $6.75 billion, while hematologic oncology revenue rose 4.6% to $1.87 billion. Neuroscience revenue climbed 19% to $1.65 billion, and aesthetics revenue was 23% higher at $1.41 billion, the company said.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

February 02, 2022 08:13 ET (13:13 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.